¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2023 ´ëÇÑ»êºÎÀΰú³»ºÐºñÇÐȸ Á¦ 31Â÷ Çмú´ëȸ ¹× ¿¬¼ö°­Á : 2023-07-16

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2023 ´ëÇÑ»êºÎÀΰú³»ºÐºñÇÐȸ Á¦ 31Â÷ Çмú´ëȸ ¹× ¿¬¼ö°­Á : 2023-07-16
±³À°ÀÏÀÚ : 2023-07-16
±³À°Àå¼Ò : ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç

±³À°ÁÖÁ¦ : 2023 ´ëÇÑ»êºÎÀΰú³»ºÐºñÇÐȸ Á¦ 31Â÷ Çмú´ëȸ ¹× ¿¬¼ö°­ÁÂ

ÁÖÃÖ±â°ü : ´ëÇÑ»êºÎÀΰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑ»êºÎÀΰú³»ºÐºñÇÐȸ

´ã´çÀÚ : ±è¹ÎÁö
¿¬¶ôó : 02-920-5310

À̸ÞÀÏ : kosge2007@empas.com

±³À°Á¾·ù : »êºÎÀΰú

Âü¼®¿¹»óÀÎ : 400¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 20ºÐ

¼¼ºÎ¼ö°­·á : 90,000¿ø  

ºñ°í »çÀüµî·Ï / ÇöÀåµî·Ïȸ¿ø50,000 / 60,000ºñȸ¿ø80,000 / 90,000Àü°øÀÇ, ÀüÀÓÀÇ, °£È£»ç40,000 / 50,000


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±âŸ 07¿ù 16ÀÏ 08:20~08:50 µî·Ï ()

±âŸ 07¿ù 16ÀÏ 08:50~08:55 °³È¸»ç ±èŹ(°í·ÁÀÇ´ë)

±âŸ 07¿ù 16ÀÏ 08:55~09:00 ÇÁ·Î±×·¥ ¼Ò°³ Á¶½ÃÇö(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 09:00~09:20 »êºÎÀΰú Áúȯ¿¡¼­ ¿¢¼ÒÁ» ¿¬±¸ÀÇ ÇöȲ°ú Àü¸Á ÀÌÀÎÇÏ(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 09:20~09:40 ÀӽŠÁß ¸é¿ªÈ°¼ºÈ­¿Í ÀÚ¼ÕÀÇ ÀÚÆó½ºÆåÆ®·³Àå¾Ö¿ÍÀÇ ¿¬°ü¼º ³ú½Å°æ°úÇб³½Ç ±èÀºÇÏ(°í·Á´ë)

Åä·Ð 07¿ù 16ÀÏ 09:40~09:50 Discussion ()

ÈÞ½Ä 07¿ù 16ÀÏ 09:50~10:10 Coffee Break ()

±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 10:10~10:30 ¿Ü·¡¿¡¼­ ÈçÈ÷ º¸´Â 'Cesarean scar niche' ÀÓ»óÀû ÀǹÌ, Áø´Ü°ú °ü¸® Á¶¹®°æ(Àü³²ÀÇ´ë)

±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 10:30~10:50 ¿Ü·¡¿¡¼­ 10ºÐ¾È¿¡ ½±°Ô ÇÒ ¼ö ÀÖ´Â ÃֽŠ¿ä½Ç±Ý ¼ö¼ú¹ý ¼Ò°³  µÎÀç±Õ(¼ÒÇÇ¾Æ ¿©¼ºÀÇ¿ø)

Åä·Ð 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 10:50~11:00 Discussion ()

±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 11:00~11:20 Screening and management of bleeding disorders in adolescents with heavy ÀÌ°æ¿í(°í·ÁÀÇ´ë)

±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 11:20~11:40 PMS¿Í PMDD ±×¸®°í menstrual migraineÀÇ Ã³¹æ knowhow. ÀÌ»ç¶ó(¿ï»êÀÇ´ë)

Åä·Ð 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 11:40~11:50 Discussion ()

±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 11:50~12:10 °æÇÇ¿¡½ºÆ®·Î°ÕÀÇ ÀåÁ¡°ú ÀÓ»óÀû¿ë ¹ÚÇöÅÂ(°í·ÁÀÇ´ë)

½Ä»ç 07¿ù 16ÀÏ 12:10~13:00 Á¡½É½Ä»ç ()

±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 13:00~13:10 Analysis of Obstetrics and Gynecology Outpatient and Inpatient Utilization Rates among Women with disabilities in Korea: the National Health Insurance Service-National Sample Cohort Study Á¤Çý°æ (°í·ÁÀÇ´ë )

±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 13:10~13:20 Efficacy of Intracorporeal Ultrasonography in Myoma Detection during Robotic Myomectomy ÀÌÁ¤À± (¼­¿ïÀÇ´ë )

±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 13:20~13:30 Characteristics of endometrial stem cells according to fertility ±èÀ¯Áø,±èÀº¿µ(Ãæ³²ÀÇ´ë)

±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 13:30~13:40 Efficacy and Safety of use of a pelubiprofen in patients with primary dysmenorrhea: A Multi-center, Randomized, Placebo-controlled, Double-blind, Cross-over, Phase 3 clinical trial Ãß¼ºÇÊ(ÀÎÇÏÀÇ´ë )

±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 13:40~13:50 Effects of exosomes derived from eutopic endometrial cells on cell proliferation and the apoptotic pathway in endometriosis and the discovery of novel exosome-related biomarkers for endometriosis ½ÅÀ¯¸®(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 13:50~14:00 The effect of sclerotherapy on ovarian reserve in patients with recurrent endometriomas Á¤¿¬¼ö(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 14:00~14:20 Àڱ󻸷Áõ ¾à¹°Ä¡·á ¾ðÁ¦±îÁö ÇؾßÇϴ°¡? Á¤À±Áö(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 14:20~14:40 ³­ÀÓȯÀÚ¿¡¼­ Àڱûù±ÙÀ°Áõ °ü¸® ¾î¶»°Ô Çϴ°¡? ±èÀ¯Áø(Ãæ³²ÀÇ´ë)

Åä·Ð 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 14:40~14:50 Discussion ()

ÈÞ½Ä 07¿ù 16ÀÏ 14:50~15:10 Coffee Break ()

±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 15:10~15:30 ¹Ýº¹À¯»êÀÇ 2022 ESHRE quideline (¹«¾ùÀÌ »õ·Î¿î °ÍÀΰ¡?) ÁÖÁ¾±æ(ºÎ»êÀÇ´ë)

±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 15:30~15:50 The 2023 PCOS international evidence-based guideline(ASRM, ESHRE, Androgen Excess and PCOS Society, Endocrine Society, European Society of Endocrinology collaborated): 2018³â°ú ±×´ë·ÎÀÎ °Í°ú ´Þ¶óÁø °ÍÀº? ±èÁøÁÖ(¼­¿ïÀÇ´ë)

Åä·Ð 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 15:50~16:00 Discussion ()

±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 16:00~16:20 Management of postmenopausal osteoporosis: ACOG 2022 guideline  (2021 position statemenr of NAMS¿ÍÀÇ Â÷ÀÌÁ¡Àº ¹«¾ùÀΰ¡?) À̵¿¿Á(±¹¸³¾Ï¼¾ÅÍ)

±³À°½Ã°£ 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 16:20~16:40 2023 Non-hormone therapy position statement of NAMS (2015³â position statement¿Í ¹Ù²ï Á¡Àº ¹«¾ùÀΰ¡?) ÀÌÀº½Ç(¼øõÇâÀÇ´ë)

Åä·Ð 07¿ù 16ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°­´ç 16:40~16:50 Discussion ()

±âŸ 07¿ù 16ÀÏ 16:50~17:00 Æóȸ»ç ±èŹ (°í·ÁÀÇ´ë)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2023 ´ëÇÑ»êºÎÀΰú³»ºÐºñÇÐȸ Á¦ 31Â÷ Çмú´ëȸ ¹× ¿¬¼ö°­Á : 2023-07-16""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2023³â ´ëÇÑÇ×±Õ¿ä¹ýÇÐȸ ºòµ¥ÀÌÅÍ ¿¬±¸È¸ ¼¼¹Ì³ª : 2023-07-17
´ÙÀ½±Û 2023³â ´ëÇÑÇǺη¹ÀÌÀúÇÐȸ Á¦24ȸ Çмú´ëȸ : 2023-07-16
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 81 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 44 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 53 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 57 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 51 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 47 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 25 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 18 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 46 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 23 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 18 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 53 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 31 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 39 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 33 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷